1-[6,7-bis(phenylmethoxy)-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-yl]-2-phenylethanone | 185104-69-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 1-[6,7-bis(phenylmethoxy)-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-yl]-2-phenylethanone
• CAS: 185104-69-2
• 化学式: C₄₁H₄₁NO₆
• 分子量: 643.78
• InChiKey: WAKLBDSXCLYQGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  48
• 可旋转键数：
  13
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  66.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-[6,7-bis(phenylmethoxy)-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-yl]-2-phenylethanone 在 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 生成 2-(2-phenylethyl)-6,7-bis(phenylmethoxy)-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinoline
  参考文献：
  名称：

  Synthesis and Evaluation of Trimetoquinol Derivatives:  Novel Thromboxane A₂/Prostaglandin H₂ Antagonists with Diminished β-Adrenergic Agonist Activity

  摘要：

  Trimetoquinol (TMQ, 1) is a unique catecholamine with a strong stereodependence for agonism at beta-adrenergic (S much greater than R) and antagonism at thromboxane A(2)/prostaglandin H-2 (TP; R much greater than S) receptors. Our laboratory has reported the effects of N-alkylation and modification of the trisubstituted benzyl group in these receptor systems. For iodinated derivative 5, maintaining potency in TP receptor systems (112%) was coupled with maintaining limited potency in beta-adrenergic receptor systems (34% for beta(1) and 47% for beta(2)) In this study, several diverse TMQ derivatives were prepared to probe for binding interactions specific to a particular receptor system. Planar amidine 2, which was designed to explore the importance of TMQ's chiral center, showed a dramatic loss of potency (<1%) in each receptor system. Likewise, the homologation of a previously described N-benzyl derivative (3) to the N-phenylethyl derivative 4 also showed reduced potency (<3%) in both receptor systems. However, modification of the trimethoxybenzyl group of TMQ to a 4-hydroxy-3-nitrobenzyl group (7) provided a unique lead for TMQ derivatives with significant potency in TP receptor systems (91%) and reduced potency in beta-adrenergic receptor systems (4% for beta(1) and 19% for beta(2)).

  DOI：

  10.1021/jm950896w
• 作为产物：
  描述：

  1-(3,4,5-trimethoxybenzyl)-6,7-bis(benzyloxy)-1,2,3,4-tetrahydroisoquinoline 、 苯乙酰氯 在 sodium carbonate 、 magnesium sulfate 作用下， 生成 1-[6,7-bis(phenylmethoxy)-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-yl]-2-phenylethanone
  参考文献：
  名称：

  Synthesis and Evaluation of Trimetoquinol Derivatives:  Novel Thromboxane A₂/Prostaglandin H₂ Antagonists with Diminished β-Adrenergic Agonist Activity

  摘要：

  Trimetoquinol (TMQ, 1) is a unique catecholamine with a strong stereodependence for agonism at beta-adrenergic (S much greater than R) and antagonism at thromboxane A(2)/prostaglandin H-2 (TP; R much greater than S) receptors. Our laboratory has reported the effects of N-alkylation and modification of the trisubstituted benzyl group in these receptor systems. For iodinated derivative 5, maintaining potency in TP receptor systems (112%) was coupled with maintaining limited potency in beta-adrenergic receptor systems (34% for beta(1) and 47% for beta(2)) In this study, several diverse TMQ derivatives were prepared to probe for binding interactions specific to a particular receptor system. Planar amidine 2, which was designed to explore the importance of TMQ's chiral center, showed a dramatic loss of potency (<1%) in each receptor system. Likewise, the homologation of a previously described N-benzyl derivative (3) to the N-phenylethyl derivative 4 also showed reduced potency (<3%) in both receptor systems. However, modification of the trimethoxybenzyl group of TMQ to a 4-hydroxy-3-nitrobenzyl group (7) provided a unique lead for TMQ derivatives with significant potency in TP receptor systems (91%) and reduced potency in beta-adrenergic receptor systems (4% for beta(1) and 19% for beta(2)).

  DOI：

  10.1021/jm950896w